Genomic analyses of HNSCC from TCGA have revealed frequent inactivating mutations of FAT1 (29%), amplifications of WWTR1 (TAZ, 14%) and YAP1 (8%), all of which associate with persistent YAP/TAZ activation and poor clinical outcome (Chowl, 2020; Moya and Halder, 2019; Dey et al., 2020; Fang et al., 2020; Chen et al., 2019)]. The gene discussed is YAP1; the disease is head and neck squamous cell carcinoma.